Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, MA, OH, NJ, X0, NH, NC, NY · listed Sep 29, 2008 → Feb 14, 2023
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
2 of 55 offerings report sales commissions totalling $2,150,000; 0 report finder's fees; 7 report proceeds to related persons totalling $5,462,460. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Nov 18, 2025 D File 021-564321 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 8, 2025 D/A File 021-478843 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 26, 2024 D File 021-530561 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 14, 2023 D File 021-473392 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 25, 2022 D File 021-438954 | $0 | $0 | $0 An affiliate of the general partner of the Issuer will receive a management fee payable by the Issuer quarterly in advance at an annual rate as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Aug 19, 2021 D File 021-410579 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 26, 2021 D File 021-390683 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 21, 2021 D File 021-387002 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 22, 2020 D/A File 021-339813 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 25, 2019 D File 021-342712 | $0 | $0 | $0 (est.) The Manager will receive a Management Fee as described in the Offering Documents. Amount is indeterminate at this time. | None listed on this filing |
| EDGAR ↗ | Nov 19, 2018 D File 021-326066 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 2, 2018 D File 021-324993 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 8, 2018 D/A File 021-314024 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 4, 2017 D File 021-300012 | $1,400,000 | $0 | $0 | Citigroup Global Markets Inc. BrokerCheck CRD 7059 ↗ Cowen and Company, LLC BrokerCheck CRD 7616 ↗ Piper Jaffray & Co. BrokerCheck CRD 665 ↗ |
| EDGAR ↗ | Oct 17, 2017 D/A File 021-249408 | $0 | $0 | $0 (est.) An affiliate of the general partner of the Issuer will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Jun 27, 2017 D File 021-289476 | $0 | $0 | $682,460 (est.) Includes salary and bonuses payable in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Jun 5, 2017 D File 021-288027 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 8, 2017 D File 021-286233 | $0 | $0 | $3,000,000 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 12, 2017 D File 021-284644 | $0 | $0 | $0 An affiliate of the general partner of the Issuer will receive a management fee payable by the Issuer quarterly in advance at an annual rate as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Oct 14, 2016 D/A File 021-271539 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 14, 2016 D/A File 021-248413 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 26, 2016 D/A File 021-240550 | $0 | $0 | $0 (est.) An affiliate of the general partner of the Issuer will receive a management fee payable by the Issuer quarterly in advance as specified in the Issuer's partnership agreement. | Crito Capital LLC BrokerCheck CRD 161724 ↗ |
| EDGAR ↗ | Apr 27, 2016 D File 021-262117 | $0 | $0 | $770,000 (est.) Ordinary course compensation for services. | None listed on this filing |
| EDGAR ↗ | Dec 30, 2015 D File 021-254201 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 25, 2015 D File 021-251985 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 6, 2015 D File 021-245207 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 5, 2015 D/A File 021-201235 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 31, 2015 D File 021-236973 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 9, 2014 D File 021-218775 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 24, 2014 D File 021-212387 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 15, 2013 D File 021-206457 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 27, 2013 D/A File 021-191213 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 3, 2013 D File 021-197362 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 15, 2013 D File 021-193359 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 4, 2013 D File 021-189531 | $0 | $0 | $150,000 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 27, 2012 D File 021-177421 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 2, 2012 D File 021-176042 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 23, 2012 D File 021-173835 | $0 | $0 | $260,000 (est.) | None listed on this filing |
| EDGAR ↗ | Oct 18, 2011 D File 021-167477 | $0 | $0 | $150,000 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 20, 2011 D File 021-158672 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Feb 7, 2011 D File 021-154945 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 29, 2010 D File 021-151089 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 15, 2010 D File 021-150537 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 26, 2010 D File 021-149574 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 24, 2010 D File 021-148139 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 23, 2010 D/A File 021-144992 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 30, 2010 D File 021-141389 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 14, 2010 D File 021-140570 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 7, 2010 D File 021-140268 | $0 | $0 | $0 (est.) The Issuer's fund manager will receive a fee for management services payable at an annual rate as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Mar 10, 2010 D/A File 021-129520 | $0 | $0 | $0 (est.) The Issuer's fund manager will receive a fee for management services payable at an annual rate as specified in the Issuer's partnership agreement. | None listed on this filing |
| EDGAR ↗ | Dec 9, 2009 D File 021-101585 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 6, 2009 D File 021-106179 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 24, 2009 D File 021-84205 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 18, 2009 D File 021-122668 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 29, 2008 D File 021-76287 | $750,000 (est.) | $0 | $450,000 (est.) | MTS Securities, LLC BrokerCheck CRD 104059 ↗ via MTS Securities, MTS (CRD 104059 ↗) |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Dualitas Therapeutics, Inc. | Director | Nov 18, 2025 | D | $66,599,990 similar: $2,000,000–$19,999,994 | $32,599,997 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Therini Bio, Inc. | Director | Sep 8, 2025 | D/A | $80,781,009 similar: $2,000,000–$19,999,994 | $74,870,150 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TRex Holdings Inc. | Director | Nov 26, 2024 | D | $85,000,000 similar: $2,000,000–$19,999,994 | $42,279,369 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Therini Bio, Inc. | Director Resigned as Director as of March 29, 2023 | Apr 14, 2023 | D | $54,617,530 similar: $2,000,000–$19,999,994 | $26,619,532 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Andovia Inc. | Director | Feb 14, 2023 | D | $1,000,000 similar: $1,100,015–$10,001,163 | $632,404 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | SV Life Sciences Fund IV CF, L.P. group: Sv Life Sciences | Executive Officer | Mar 25, 2022 | D | $421,446,223 similar: $155,000–$5,250,000 | $421,446,223 | 44 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Eyebiotech Ltd | Executive Officer | Aug 19, 2021 | D | $486 similar: $1,694,259–$16,000,000 | $486 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Xilio Therapeutics, Inc. | Director | Feb 26, 2021 | D | $94,999,989 similar: $2,000,000–$19,999,994 | $94,999,989 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Xilio Therapeutics, Inc. | Director | Jan 21, 2021 | D | $50,249,990 similar: $2,000,000–$19,999,994 | $50,249,990 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Therini Bio, Inc. | Director | May 22, 2020 | D/A | $9,356,749 similar: $2,000,000–$19,999,994 | $9,356,749 | 4 similar: 2–16 | $1 similar: $10,000–$50,000 |
| EDGAR ↗ | SV7 Impact Medicine Fund LP group: Sv Life Sciences | Executive Officer Investment Committee Member | Jun 25, 2019 | D | $250,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Ribometrix, Inc. | Director | Nov 19, 2018 | D | $29,999,996 similar: $1,694,259–$16,000,000 | $14,999,998 | 16 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Ophthotech Corp. | Director | Nov 2, 2018 | D | $11,694,883 similar: $2,000,000–$19,999,994 | $11,399,894 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SUTRO BIOPHARMA INC | Director | Aug 8, 2018 | D/A | $85,382,351 similar: $2,000,000–$19,999,994 | $85,382,349 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SUTRO BIOPHARMA INC | Director | Jun 6, 2018 | D | $60,000,000 similar: $2,000,000–$19,999,994 | $31,624,999 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Dec 4, 2017 | D | $20,000,000 similar: $2,000,000–$14,000,000 | $20,000,000 | 1 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Dementia Discovery LP group: Sv Life Sciences | Executive Officer | Oct 17, 2017 | D/A | $302,381,000 similar: $155,000–$5,250,000 | $25,967,331 | 3 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Avitide, Inc. | Director | Jun 27, 2017 | D | $11,999,962 similar: $1,694,259–$16,000,000 | $11,999,962 | 10 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Deciphera Pharmaceuticals, LLC | Director | Jun 5, 2017 | D | $52,299,628 similar: $2,000,000–$19,999,994 | $52,299,628 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | May 8, 2017 | D | $50,539,341 similar: $2,000,000–$19,999,994 | $45,539,314 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SV Life Sciences Fund VI Strategic Partners, L.P. group: Sv Life Sciences | Executive Officer | Apr 12, 2017 | D | $13,130,000 similar: $155,000–$5,250,000 | $13,130,000 | 35 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Dementia Discovery LP group: Sv Life Sciences | Executive Officer | Oct 17, 2016 | D/A | $200,000,000 similar: $155,000–$5,250,000 | $24,102,787 | 3 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | AmeriClean Holdings LLC group: Strength | Executive Officer, Director | Oct 14, 2016 | D/A | $11,049,338 similar: $650,000–$6,000,000 | $11,049,338 | 25 similar: 1–11 | No minimum reported similar: $9,999–$50,000 |
| EDGAR ↗ | Deciphera Pharmaceuticals, LLC | Director | Jul 14, 2016 | D/A | $90,604,034 similar: $1,694,259–$16,000,000 | $90,604,034 | 5 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | SV Life Sciences Fund VI, L.P. group: Sv Life Sciences | Executive Officer | May 26, 2016 | D/A | $400,000,000 similar: $155,000–$5,250,000 | $273,500,000 | 24 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Apr 27, 2016 | D | $15,007,220 similar: $2,000,000–$19,999,994 | $15,007,220 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Dec 30, 2015 | D | $4,000,000 similar: $2,000,000–$19,999,994 | $4,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lucina Health, Inc. | Director | Nov 25, 2015 | D | $1,763,000 similar: $829,831–$9,999,998 | $1,763,000 | 10 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Dementia Discovery LP group: Sv Life Sciences | Executive Officer | Oct 15, 2015 | D | $200,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Avitide, Inc. | Director | Aug 6, 2015 | D | $7,663,840 similar: $2,000,000–$19,999,994 | $3,831,920 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Jun 5, 2015 | D/A | $20,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SV Life Sciences Fund VI, L.P. group: Sv Life Sciences | Executive Officer | May 26, 2015 | D | $400,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | CATABASIS PHARMACEUTICALS INC | Director | Mar 31, 2015 | D | $20,358,737 similar: $1,694,259–$16,000,000 | $12,413,736 | 20 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Aug 11, 2014 | D/A | $20,000,000 similar: $2,000,000–$19,999,994 | $12,999,999 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Avitide, Inc. | Director | Jun 9, 2014 | D | $3,435,003 similar: $2,000,000–$19,999,994 | $3,435,003 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | THESAN PHARMACEUTICALS, INC. | Director | Feb 24, 2014 | D | $49,513,148 similar: $1,694,259–$16,000,000 | $17,399,999 | 5 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CATABASIS PHARMACEUTICALS INC | Director | Nov 15, 2013 | D | $32,433,331 similar: $1,694,259–$16,000,000 | $32,433,331 | 11 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Aug 13, 2013 | D | $20,000,000 similar: $2,000,000–$19,999,994 | $12,999,999 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATABASIS PHARMACEUTICALS INC | Director | Jun 27, 2013 | D/A | $9,195,865 similar: $1,694,259–$16,000,000 | $9,195,865 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Ophthotech Corp. | Director | Jun 3, 2013 | D | $50,000,000 similar: $2,000,000–$19,999,994 | $16,666,668 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Avitide, Inc. | Director | Mar 15, 2013 | D | $1,449,999 similar: $2,000,000–$19,999,994 | $1,449,999 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATABASIS PHARMACEUTICALS INC | Director | Feb 1, 2013 | D | $8,749,999 similar: $1,694,259–$16,000,000 | $8,749,999 | 5 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Lucina Health, Inc. | Director | Jan 4, 2013 | D | $2,855,000 similar: $829,831–$9,999,998 | $2,000,000 | 6 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Abcam plc | Director | Apr 27, 2012 | D | $76,999,653 similar: $2,000,000–$19,999,994 | $76,999,653 | 118 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Adimab, LLC group: Adimab | Director | Apr 2, 2012 | D | $13,816,447 similar: $2,000,000–$19,999,994 | $13,816,447 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lucina Health, Inc. | Director | Feb 23, 2012 | D | $3,000,000 similar: $829,831–$9,999,998 | $2,000,000 | 5 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Lucina Health, Inc. | Director | Oct 18, 2011 | D | $3,475,002 similar: $829,831–$9,999,998 | $3,475,002 | 6 similar: 2–15 | $37,500 similar: $10,000–$54,310 |
| EDGAR ↗ | Link Medicine Corp | Director | Apr 20, 2011 | D | $4,808,500 similar: $2,000,000–$19,999,994 | $4,808,500 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Feb 7, 2011 | D | $9,600,002 similar: $2,000,000–$19,999,994 | $9,600,002 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Adimab, Inc. group: Adimab | Director | Nov 29, 2010 | D | $3,999,909 similar: $2,000,000–$19,999,994 | $3,999,909 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Balance Health Corp | Director | Nov 15, 2010 | D | $500,000 similar: $500,000–$7,000,000 | $500,000 | 3 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | JUVARIS BIO THERAPEUTICS INC | Director | Oct 26, 2010 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $750,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Sep 24, 2010 | D | $400,002 similar: $2,000,000–$19,999,994 | $400,002 | 7 similar: 2–16 | $882 similar: $10,000–$50,000 |
| EDGAR ↗ | Lucina Health, Inc. | Director | Jul 23, 2010 | D/A | $3,125,000 similar: $829,831–$9,999,998 | $3,125,000 | 7 similar: 2–15 | $49,999 similar: $10,000–$54,310 |
| EDGAR ↗ | Lucina Health, Inc. | Director | Jul 15, 2010 | D | $4,520,467 | $4,520,467 | 7 | $49,999 |
| EDGAR ↗ | Link Medicine Corp | Director | Apr 30, 2010 | D | $20,000,003 similar: $2,000,000–$19,999,994 | $20,000,003 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATABASIS PHARMACEUTICALS INC | Director | Apr 14, 2010 | D | $39,740,526 similar: $1,694,259–$16,000,000 | $7,740,526 | 15 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | SV Life Sciences Fund V Strategic Partners, L.P. group: Sv Life Sciences | Executive Officer Member of the GP LLC | Apr 7, 2010 | D | $10,575,000 | $10,575,000 | 68 | $25,000 |
| EDGAR ↗ | SV LIFE SCIENCES FUND V LP group: Sv Life Sciences | Executive Officer Member of the GP LLC | Mar 10, 2010 | D/A | $500,000,000 | $407,226,805 | 42 | No minimum reported |
| EDGAR ↗ | Ikano Therapeutics Inc. | Director | Dec 9, 2009 | D | Indefinite similar: $1,694,259–$16,000,000 | $892,719 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Adimab, Inc. group: Adimab | Director | Oct 6, 2009 | D | $8,205,751 similar: $2,000,000–$19,999,994 | $8,205,751 | 10 similar: 2–16 | $633 similar: $10,000–$50,000 |
| EDGAR ↗ | JUVARIS BIO THERAPEUTICS INC | Director | Sep 24, 2009 | D | $25,150,000 similar: $2,000,000–$19,999,994 | $15,136,247 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lucina Health, Inc. | Director | May 18, 2009 | D | $4,000,000 | $4,000,000 | 5 | $114,864 |
| EDGAR ↗ | Link Medicine Corp | Director | Sep 29, 2008 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $40,000,000 | 4 similar: 2–16 | $300,000 similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (8 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Michael Ross. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Michael Ross appears on a new Form D, or when a court case or SEC action is matched to them. See plans →